Napoleone Ferrara
University of California, San Diego
Vascular endothelial growth factor CCancerEndothelial stem cellInternal medicineEndocrinologyPathologyVascular endothelial growth factor AVascular endothelial growth factor BMolecular biologyReceptorChemistryImmunologyGrowth factorEndotheliumVascular endothelial growth factorNeovascularizationAngiogenesisCancer researchMedicineBiologyCell biology
371Publications
179H-index
125kCitations
Publications 362
Newest
#1Deepak SampathH-Index: 44
#2Jason OehH-Index: 15
Last. Richard A.D. CaranoH-Index: 53
view all 21 authors...
The phosphatidylinositol 3-kinase (PI3K) pathway is a central mediator of vascular endothelial growth factor (VEGF)–driven angiogenesis. The discovery of small molecule inhibitors that selectively target PI3K or PI3K and mammalian target of rapamycin (mTOR) provides an opportunity to pharmacologically determine the contribution of these key signaling nodes in VEGF-A–driven tumor angiogenesis in vivo. This study used an array of microvascular imaging techniques to monitor the antivascular effects...
#1Adi Ben Shoham (Weizmann Institute of Science)H-Index: 4
#2Guy Malkinson (Weizmann Institute of Science)H-Index: 12
Last. Elazar Zelzer (Weizmann Institute of Science)H-Index: 31
view all 8 authors...
Coordination between the vascular system and forming organs is essential for proper embryonic development. The vasculature expands by sprouting angiogenesis, during which tip cells form filopodia that incorporate into capillary loops. Although several molecules, such as vascular endothelial growth factor A (Vegfa), are known to induce sprouting, the mechanism that terminates this process to ensure neovessel stability is still unknown. Sphingosine-1-phosphate receptor 1 (S1P1) has been shown to m...
74 CitationsSource
#1Jing Jin (MSH: Mount Sinai Hospital, Toronto)H-Index: 38
#2Karen Sison (MSH: Mount Sinai Hospital, Toronto)H-Index: 6
Last. Susan E. Quaggin (MSH: Mount Sinai Hospital, Toronto)H-Index: 68
view all 18 authors...
Vascular endothelial growth factor and its receptors, FLK1/KDR and FLT1, are key regulators of angiogenesis. Unlike FLK1/KDR, the role of FLT1 has remained elusive. FLT1 is produced as soluble (sFLT1) and full-length isoforms. Here, we show that pericytes from multiple tissues produce sFLT1. To define the biologic role of sFLT1, we chose the glomerular microvasculature as a model system. Deletion of Flt1 from specialized glomerular pericytes, known as podocytes, causes reorganization of their cy...
109 CitationsSource
#1Yanqiu Liu (Harvard University)H-Index: 4
#2Agnes D. BerendsenH-Index: 16
Last. Bjorn R. OlsenH-Index: 133
view all 7 authors...
Osteoporotic bones have reduced spongy bone mass, altered bone architecture, and increased marrow fat. Bone marrow stem cells from osteoporotic patients are more likely to differentiate into adipocytes than control cells, suggesting that adipocyte differentiation may play a role in osteoporosis. VEGF is highly expressed in osteoblastic precursor cells and is known to stimulate bone formation. Here we tested the hypothesis that VEGF is also an important regulator of cell fate, determining whether...
237 CitationsSource
#1Guanglei Zhuang (Genentech)H-Index: 25
#2Xiumin Wu (Genentech)H-Index: 28
Last. Napoleone Ferrara (Genentech)H-Index: 179
view all 11 authors...
Angiogenesis plays a crucial role during tumorigenesis and much progress has been recently made in elucidating the role of VEGF and other growth factors in the regulation of angiogenesis. Recently, microRNAs (miRNAs) have been shown to modulate a variety of physiogical and pathological processes. We identified a set of differentially expressed miRNAs in microvascular endothelial cells co-cultured with tumour cells. Unexpectedly, most miRNAs were derived from tumour cells, packaged into microvesi...
315 CitationsSource
#1Alicia S. Chung (Genentech)H-Index: 8
#2Marcin Kowanetz (Genentech)H-Index: 41
Last. Napoleone Ferrara (Genentech)H-Index: 179
view all 9 authors...
Inhibiting angiogenesis has become an important therapeutic strategy for cancer treatment but, like other current targeted therapies, benefits experienced for late-stage cancers can be curtailed by inherent refractoriness or by acquired drug resistance, requiring a need for better mechanistic understanding of such effects. Numerous preclinical studies have demonstrated that VEGF pathway inhibitors suppress primary tumour growth and metastasis. However, it has been recently reported that short-te...
67 CitationsSource
#1Mallika Singh (Genentech)H-Index: 18
#2Suzana S. Couto (Genentech)H-Index: 15
Last. Leisa Johnson (Genentech)H-Index: 13
view all 21 authors...
Resistance to anti-angiogenic therapy can occur via several potential mechanisms. Unexpectedly, recent studies showed that short-term inhibition of either VEGF or VEGFR enhanced tumour invasiveness and metastatic spread in preclinical models. In an effort to evaluate the translational relevance of these findings, we examined the consequences of long-term anti-VEGF monoclonal antibody therapy in several well-validated genetically engineered mouse tumour models of either neuroendocrine or epitheli...
60 CitationsSource
#1Sebastian Willenborg (University of Cologne)H-Index: 9
#2Tina Lucas (University of Cologne)H-Index: 12
Last. Sabine A. Eming (University of Cologne)H-Index: 46
view all 12 authors...
Monocytes/macrophages are critical in orchestrating the tissue-repair response. However, the mechanisms that govern macrophage regenerative activities during the sequential phases of repair are largely unknown. In the present study, we examined the dynamics and functions of diverse monocyte/macrophage phenotypes during the sequential stages of skin repair. By combining the analysis of a new CCR2-eGFP reporter mouse model with conditional mouse mutants defective in myeloid cell–restricted CCR2 si...
266 CitationsSource
#1Azeb Tadesse ArgawH-Index: 6
#2Linnea Asp (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 5
Last. Gareth R. JohnH-Index: 29
view all 13 authors...
In inflammatory CNS conditions such as multiple sclerosis (MS), current options to treat clinical relapse are limited, and more selective agents are needed. Disruption of the blood-brain barrier (BBB) is an early feature of lesion formation that correlates with clinical exacerbation, leading to edema, excitotoxicity, and entry of serum proteins and inflammatory cells. Here, we identify astrocytic expression of VEGF-A as a key driver of BBB permeability in mice. Inactivation of astrocytic Vegfa e...
346 CitationsSource
#1Mallika Singh (Novartis)H-Index: 18
#2Napoleone Ferrara (Genentech)H-Index: 179
Abstract Abstract• References• Author information Disappointing results from most late-stage clinical trials of cancer therapeutics indicate a need for improved and more-predictive animal tumor models. This insufficiency of models, combined with the advent of a class of drugs that target the tumor microenvironment rather than the tumor cell, presents new challenges for designing and interpreting preclinical efficacy studies. A comparison of the clinical efficacy of anti-angiogenic drugs with the...
84 CitationsSource